References
- United Nations resolution 61/225. World diabetes day [Internet]. [cited 2016 May]. Available from: https://www.idf.org/sites/default/files/UN%20Resolution%20on%20World%20Diabetes%20Day%20of%20Dec%202006.pdf
- International diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org.
- International diabetes federation: living guide [Internet]. [cited 2015 Dec 31]. Available from: www.idf.org/WDD15-guide/facts-and-figures.
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
- Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
- Type 2 diabetes in adults: management [Internet]. NICE guideline NG28; 2015 Dec. [cited 2016 May]. Available from: https://www.nice.org.uk/guidance/ng28
- American Diabetes Association. Antihyperglycaemic therapy in type 2 diabetes: general recommendations. Diabetes Care. 2014;37:S14–S80.
- The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
- The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
- Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307.
- Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109. doi:10.1111/jdi.12490
- Japanese Regulatory Authority. Pharmaceutical and medical devices agency (PMDA). 2015. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.
- Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabetic Med. 2002;19(4):279–284.
- http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5566.
- Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18:333–347.
- Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-1032): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014;57:3205–3212.
- Addy C, Tatosian D, Glasgow XS, et al. Pharmacokinetic and pharmacodynamic effects of multiple-dose administration of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in obese participants with and without Type 2 diabetes mellitus. Clin Ther. 2016;38(3):516–530.
- Sheu W-H-H, Gantz I, Chen M, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once weekly DPP-4 inhibitor for the treatment of patients with Type 2 diabetes. Diabetes Care. 2015;38:2106–2114.
- A study of omarigliptin (MK-3102) in participants with impaired renal function [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01407276.
- Krishna R, Addy C, Tatosian D, et al. Pharmacokinetics and pharmacodynamics of Omarigliptin, a once-weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, after single and multiple doses in healthy subjects. J Clin Pharmacol. 2016. doi:10.1002/jcph.773.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
- Gantz I, Lai E, Suryawanshi S. Omarigliptin a once weekly DPP-4 inhibitor, provides similar glycaemic control to sitaglitpin in patients with Type 2 diabetes mellitus inadequately controlled on metformin. Presentation at 51st EASD Annual Meeting; 2015 Sep 15, Stockholm.
- A study of the safety and efficacy of omarigliptin (MK-3102) compared with glimepiride in participants with Type 2 diabetes mellitus with inadequate glycemic control on metformin (MK-3102-016) [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01682759.
- Addition of omarigliptin (MK-3102) to participants with Type 2 diabetes mellitus who have inadequate glycemic control on combination therapy with glimepiride and metformin (MK-3102-022) [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01704261.
- A study of the safety and efficacy of MK-3102 in ≥18 and <45 year-old subjects with Type 2 diabetes mellitus and inadequate glycemic control (MK-3102-028) [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01814748.
- A study of MK-3102 in participants with Type 2 diabetes mellitus with chronic kidney disease or kidney failure on dialysis (MK-3102-019) [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01698775.
- Tsuchiya S, Freidaman E, Addy C, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once weekly dipeptidyl peptidase-4 inhibitor in healthy Japanese male subjects. J Diabetes Investig. 2016. doi:10.1111/jdi.12538.
- Tatosian D, Marricco NC, Glasgow XS, et al. PO10 A supertherapeutic dose of Omarigliptin, a once weekly DPP-4 inhibitor, does not prolong the QTc interval. Clinical pharmacology in drug development. 2016 [cited 2016 Apr 6]. Available from: https://www.researchgate.net/publication/296683633_A_Thorough_QTc_Study_Confirms_Early_PharmacokineticsQTc_Modeling_A_Supratherapeutic_Dose_of_Omarigliptin_A_Once-Weekly_DPP-4_Inhibitor_Does_Not_Prolong_the_QTc_Interval.
- A randomized, double-blind, placebo-controlled, multicenter study to assess cardiovascular outcomes following treatment with MK-3102 in subjects with Type 2 diabetes mellitus [cited 2016 Apr 6]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002414-39/DK.
- Inzucchi SI, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 diabetes: 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38(1):140–149.
- Type 2 diabetes in adults: management [Internet]. [cited 2016 May]. Available from: https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-1837338615493.
- Benjamin M, Scirica BM, Bhatt DL, et al. Saxagliptin and cardiovascular outcomes in patients with Type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
- White WB, Cannon CP, Heller SR. Alogliptin after acute coronary syndrome in patients with Type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
- Green JB, Bethel MA, Armstrong PW. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373:232–242.
- Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016. doi:10.1056/NEJMoa1603827.
- EASD. 2016. [cited 2016 Apr 29]. Available from: http://www.medscape.com/viewarticle/862644.